RT Journal Article
SR Electronic
T1 Accessible LAMP-Enabled Rapid Test (ALERT) for detecting SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.18.21251793
DO 10.1101/2021.02.18.21251793
A1 Ali Bektaş
A1 Michael F. Covington
A1 Guy Aidelberg
A1 Anibal Arce
A1 Tamara Matute
A1 Isaac Núñez
A1 Julia Walsh
A1 David Boutboul
A1 Ariel B. Lindner
A1 Fernán Federici
A1 Anitha Jayaprakash
YR 2021
UL http://medrxiv.org/content/early/2021/02/20/2021.02.18.21251793.abstract
AB The COVID-19 pandemic has highlighted bottlenecks in large-scale, frequent testing of populations for infections. PCR-based diagnostic tests are expensive, reliant on expensive centralized labs, can take days to deliver results, and are prone to backlogs and supply shortages. Antigen tests, that bind and detect the surface proteins of a virus, are rapid and inexpensive but suffer from high false negative rates. To address this problem, we have created an inexpensive, simple, and robust 60-minute Do-It-Yourself (DIY) workflow to detect viral RNA from nasal swabs or saliva with high sensitivity (0.1 to 2 viral particles/µl) and specificity (>97% True Negative Rate) utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP).Our workflow, ALERT (Accessible LAMP-Enabled Rapid Test), incorporates the following features: 1) Increased shelf-life and ambient temperature storage by using wax layers to isolate enzymes from reaction, 2) Improved specificity by using sequence-specific QUASR reporters, 3) Increased sensitivity through use of a magnetic wand to enable pipette-free concentration of sample RNA and cell debris removal, 4) Quality control with a nasopharyngeal-specific mRNA target, and 5) Co-detection of other respiratory viruses, such as Influenza B, by duplexing QUASR-modified RT-LAMP primer sets.The flexible nature of the ALERT workflow allows easy, at-home and point-of-care testing for individuals and higher-throughput processing for centralized labs and hospitals. With minimal effort, SARS-CoV-2-specific primer sets can be swapped out for other targets to repurpose ALERT to detect other viruses, microorganisms or nucleic acid-based markers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a microgrant from Just One Giant Lab (JOGL) and a COVID Catalyst Grant from the Henry Wheeler Center for Emerging Diseases (CEND) at the University of California Berkeley. FF, AA, TM, and IN were funded by ANID - Millennium Science Initiative Program -ICN17_022; FF and TM were supported by ANID CONCYTEC covbio0012.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comié de Ética y Bioseguridad at Pontificia Universidad Católica de ChileAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript.